Patents by Inventor Robert G. Schmidt

Robert G. Schmidt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyrrolidine Main Protease Inhibitors as Antiviral Agents
    Publication number: 20240158368
    Abstract: Pyrrolidine main protease inhibitors are described that are effective as antiviral compounds.
    Type: Application
    Filed: October 12, 2023
    Publication date: May 16, 2024
    Applicant: AbbVie Inc.
    Inventors: David A. Degoey, Michael R. Schrimpf, David J. Hardee, Jacob Ludwig, Eric R. Miller, Timothy R. Hodges, Alberto Munoz, Sarah J. Perlmutter, Huan-Qiu X. Li, Alvin Jang, Elizabeth L. Noey, Gregory A. Gfesser, Edgars Jecs, Robert G. Schmidt, Justin D. Dietrich, Xenia B. Searle, Boguslaw P. Nocek, Andrew Bogdan
  • Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
    Publication number: 20220211692
    Abstract: The present invention provides for compounds of Formula (I) wherein R1, R2, R3, m and n have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
    Type: Application
    Filed: December 17, 2021
    Publication date: July 7, 2022
    Applicant: AbbVie Global Enterprises Ltd.
    Inventors: David J. Hardee, Timothy R. Hodges, Robert G. Schmidt, Michael R. Schrimpf, Xenia B. Searle
  • TRPV3 MODULATORS
    Publication number: 20180243298
    Abstract: A compound of Formula (I) having efficacy for the treatment or prevention of conditions and disorders related to TRPV3 activity, e.g. pain, atopic dermatitis, eczema, itch or psoriasis, is disclosed. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.
    Type: Application
    Filed: March 30, 2016
    Publication date: August 30, 2018
    Inventors: Lawrence Black, Brian S. Brown, Bruce Clapham, Marlon D. Cowart, Michael J. Dart, Ramin Faghih, Jennifer Frost, Arthur R. Gomtsyan, Philip R. Kym, Huaqing Liu, Robert G. Schmidt, Lei Shi, Anurupa Shrestha, Kevin Sippy
  • TRPV3 modulators
    Patent number: 9012651
    Abstract: Disclosed herein are modulators of TRPV3 of formula (I) wherein X1, X2, R1, R2, Rx, and n are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.
    Type: Grant
    Filed: March 23, 2012
    Date of Patent: April 21, 2015
    Assignee: AbbVie Inc.
    Inventors: Bruce Clapham, Phil B. Cox, Michael J. Dart, Arthur Gomtsyan, Tammie K. Jinkerson, Ryan G. Keddy, Michael E. Kort, Philip R. Kym, Mark Matulenko, Robert G. Schmidt, Clara I. Villamil, Eric A. Voight, Kevin R. Woller
  • TRPV3 modulators
    Patent number: 8772499
    Abstract: Disclosed herein are modulators of TRPV3 of Formula (I) wherein p is 1, 2, 3, or 4, and G1, X1, X2, X3, X4, X5, G2, Z1, Ra, Rb, and u are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.
    Type: Grant
    Filed: October 23, 2012
    Date of Patent: July 8, 2014
    Assignee: AbbVie Inc.
    Inventors: Erol K. Bayburt, Bruce Clapham, Phil B. Cox, Jerome F. Daanen, Michael J. Dart, Gregory A. Gfesser, Arthur Gomtsyan, Michael E. Kort, Philip R. Kym, Robert G. Schmidt, Eric A. Voight
  • TRPV3 modulators
    Patent number: 8772500
    Abstract: Disclosed herein are modulators of TRPV3 of formula (II): wherein G1, X1, X2, X3, X4, X5, G2, Ra, Rb, and u are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.
    Type: Grant
    Filed: October 23, 2012
    Date of Patent: July 8, 2014
    Assignee: AbbVie Inc.
    Inventors: Erol K. Bayburt, Bruce Clapham, Phil B. Cox, Jerome F. Daanen, Michael J. Dart, Gregory A. Gfesser, Arthur Gomtsyan, Michael E. Kort, Philip R. Kym, Robert G. Schmidt
  • NOVEL TRPV3 MODULATORS
    Publication number: 20140080803
    Abstract: Disclosed herein are modulators of TRPV3 of Formula (I) wherein p is 1, 2, 3, or 4, and G1, X1, X2, X3, X4, X5, G2, Z1, Ra, Rb, and u are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.
    Type: Application
    Filed: October 23, 2012
    Publication date: March 20, 2014
    Applicant: AbbVie Inc.
    Inventors: Erol K. Bayburt, Bruce Clapham, Phil B. Cox, Jerome F. Daanen, Michael J. Dart, Gregory A. Gfesser, Arthur Gomtsyan, Michael E. Kort, Philip R. Kym, Robert G. Schmidt, Eric A. Voight
  • TRPV1 antagonists
    Patent number: 8609692
    Abstract: Disclosed herein are compounds of formula (I), or pharmaceutically acceptable salts, solvates, prodrugs, salts of prodrugs, or combinations thereof, wherein R1, R2, R3, R4, and m are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
    Type: Grant
    Filed: October 15, 2009
    Date of Patent: December 17, 2013
    Assignee: AbbVie Inc.
    Inventors: Arthur R. Gomtsyan, Erol K. Bayburt, Jun Chen, Stanley DiDomenico, Jerome F. Daanen, Michael E. Kort, Philip R. Kym, Heath A. McDonald, Richard J. Perner, Robert G. Schmidt, Eric A. Voight
  • TRPV1 antagonists
    Patent number: 8604053
    Abstract: Disclosed herein are compounds of formula (I) or pharmaceutically acceptable salts, solvates, prodrugs, salts of prodrugs, or combinations thereof, wherein R1, R2, R3, R4, and m are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
    Type: Grant
    Filed: October 15, 2009
    Date of Patent: December 10, 2013
    Assignee: AbbVie Inc.
    Inventors: Arthur R. Gomtsyan, Eric A. Voight, Erol K. Bayburt, Jun Chen, Jerome F. Daanen, Stanley DiDomenico, Michael E. Kort, Philip R. Kym, Heath A. McDonald, Richard J. Perner, Robert G. Schmidt
  • Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
    Patent number: 8487116
    Abstract: The present invention discloses novel compounds of general formula (I) or a pharmaceutically acceptable salt or prodrug thereof (in which X1-X5, R5-R8b, Z1-Z2 and Ar1 are defined herein), a method for inhibiting the VR1 receptor in mammals using these compounds, a method for controlling pain in mammals, and pharmaceutical compositions including those compounds and a process for making those compounds.
    Type: Grant
    Filed: November 9, 2011
    Date of Patent: July 16, 2013
    Assignee: AbbVie Inc.
    Inventors: Arthur R. Gomtsyan, Erol K. Bayburt, John R. Koenig, Chih-Hung Lee, Robert G. Schmidt, Kirill A. Lukin, Gilles Chambournier, Margaret Chi-Ping Hsu, Robert M. Leanna, Russell D. Cink
  • Antagonists of the TRPV1 receptor and uses thereof
    Patent number: 8350083
    Abstract: The present application is directed to compounds that are TRPV1 antagonists and have formula (I) wherein variables Ar1, L1, R1, R2, R3, R4, R5, Y1, Y2, and Y3, are as defined in the description, which are useful for treating disorders caused by or exacerbated by vanilloid receptor activity.
    Type: Grant
    Filed: September 29, 2011
    Date of Patent: January 8, 2013
    Assignee: AbbVie Inc.
    Inventors: Arthur R. Gomtsyan, Robert G. Schmidt, Jerome F. Daanen, Erol K. Bayburt, Chih-hung Lee, Steven P. Latshaw
  • TRPV1 antagonists
    Patent number: 8338603
    Abstract: The present invention relates to compounds of formula (I) wherein X, R1, R2, R3, R4, R5, m, and n are defined in the specification are TRPV1 antagonists. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
    Type: Grant
    Filed: December 27, 2011
    Date of Patent: December 25, 2012
    Assignee: AbbVie Inc.
    Inventors: Arthur R. Gomtsyan, Robert G. Schmidt, Erol K. Bayburt, Jerome F. Daanen, Michael E. Kort
  • TRPV3 Modulators
    Publication number: 20120245124
    Abstract: Disclosed herein are modulators of TRPV3 of formula (I) wherein X1, X2, R1, R2, Rx, and n are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.
    Type: Application
    Filed: March 23, 2012
    Publication date: September 27, 2012
    Applicant: ABBOTT LABORATORIES
    Inventors: Bruce Clapham, Phil B. Cox, Michael J. Dart, Arthur Gomtsyan, Tammie K. Jinkerson, Ryan G. Keddy, Michael E. Kort, Philip R. Kym, Mark Matulenko, Robert G. Schmidt, Clara I. Villamil, Eric A. Voight, Kevin R. Woller
  • FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR
    Publication number: 20120190845
    Abstract: The present invention discloses novel compounds of general formula (I) or a pharmaceutically acceptable salt or prodrug thereof (in which X1-X5, R5-R8b, Z1-Z2 and Ar1 are defined herein), a method for inhibiting the VR1 receptor in mammals using these compounds, a method for controlling pain in mammals, and pharmaceutical compositions including those compounds and a process for making those compounds.
    Type: Application
    Filed: November 9, 2011
    Publication date: July 26, 2012
    Inventors: Arthur R. Gomtsyan, Erol K. Bayburt, Chih-Hung Lee, John R. Koenig, Robert G. Schmidt, Kirill A. Lukin, Gilles Chamboumier, Margaret Chi-Ping Hsu, Robert M. Leanna, Russell D. Cink
  • TRPV1 ANTAGONISTS
    Publication number: 20120108642
    Abstract: The present invention relates to compounds of formula (I) wherein X, R1, R2, R3, R4, R5, m, and n are defined in the specification are TRPV1 antagonists. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
    Type: Application
    Filed: December 27, 2011
    Publication date: May 3, 2012
    Inventors: Arthur R. Gomtsyan, Robert G. Schmidt, Erol K. Bayburt, Jerome F. Daanen, Michael E. Kort
  • TRPV1 antagonists
    Patent number: 8084616
    Abstract: The present invention relates to compounds of formula (I) wherein X, R1, R2, R3, R4, R5, m, and n are defined in the specification are TRPV1 antagonists. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
    Type: Grant
    Filed: October 23, 2008
    Date of Patent: December 27, 2011
    Assignee: Abbott Laboratories
    Inventors: Arthur R. Gomtsyan, Robert G. Schmidt, Erol K. Bayburt, Jerome F. Daanen, Michael E. Kort
  • Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
    Patent number: 8071762
    Abstract: The present invention discloses novel compounds of general formula (I) or a pharmaceutically acceptable salt or prodrug thereof (in which X1-X5, R5-R8b, Z1-Z2 and Ar1 are defined herein), a method for inhibiting the VR1 receptor in mammals using these compounds, a method for controlling pain in mammals, and pharmaceutical compositions including those compounds and a process for making those compounds.
    Type: Grant
    Filed: April 30, 2008
    Date of Patent: December 6, 2011
    Assignee: Abbott Laboratories
    Inventors: Arthur R. Gomtsyan, Erol K. Bayburt, Chih-Hung Lee, John R. Koenig, Robert G. Schmidt, Kirill A. Lukin, Gilles Chambournier, Margaret Chi-Ping Hsu, Marvin R. Leanna, Russell D. Cink
  • TRPV1 antagonists
    Patent number: 7998993
    Abstract: Compounds of formula (I) wherein R1, R2, R4, and W are defined in the description are TRPV 1 antagonists with CNS penetration. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
    Type: Grant
    Filed: October 23, 2008
    Date of Patent: August 16, 2011
    Assignee: Abbott Laboratories
    Inventors: Richard J. Perner, John R. Koenig, Stanley DiDomenico, Jr., Erol K. Bayburt, Jerome F. Daanen, Arthur Gomtsyan, Michael E. Kort, Philip R. Kym, Robert G. Schmidt, Anil Vasudevan, Eric Voight
  • TRPV1 ANTAGONISTS
    Publication number: 20100137360
    Abstract: Disclosed herein are compounds of formula (I) or pharmaceutically acceptable salts, solvates, prodrugs, salts of prodrugs, or combinations thereof, wherein R1, R2, R3, R4, and m are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
    Type: Application
    Filed: October 15, 2009
    Publication date: June 3, 2010
    Applicant: ABBOTT LABORATORIES
    Inventors: Arthur R. Gomtsyan, Eric A. Voight, Erol K. Bayburt, Jun Chen, Jerome F. Daanen, Stanley DiDomenico, Michael E. Kort, Philip R. Kym, Heath A. McDonald, Richard J. Perner, Robert G. Schmidt
  • TRPV1 ANTAGONISTS
    Publication number: 20100120846
    Abstract: Disclosed herein are compounds of formula (I), or pharmaceutically acceptable salts, solvates, prodrugs, salts of prodrugs, or combinations thereof, wherein R1, R2, R3, R4, and m are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
    Type: Application
    Filed: October 15, 2009
    Publication date: May 13, 2010
    Applicant: ABBOTT LABORATORIES
    Inventors: Arthur R. Gomtsyan, Erol K. Bayburt, Jun Chen, Stanley DiDomenico, Jerome F. Daanen, Michael E. Kort, Philip R. Kym, Heath A. McDonald, Richard J. Perner, Robert G. Schmidt, Eric A. Voight